Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review
Open accessPublished version of a preprint
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: It is estimated that up to 75% of patients with severe mental illness (SMI) also have substance use disorder (SUD). The aim of this systematic review was to explore the scope, quality and inclusivity of international clinical guidelines on mental health and/or substance abuse in relation to diagnosis and treatment of co-existing disorders and considerations for wider social and contextual factors in treatment recommendations. Method: A protocol (PROSPERO CRD42020187094) driven systematic review was conducted. A systematic search was undertaken using six databases including MEDLINE, Cochrane Library, EMBASE, PsychInfo from 2010 till June 2020; and webpages of guideline bodies and professional societies. Guideline quality was assessed based on ‘Appraisal of Guidelines for Research & Evaluation II’ (AGREE II) tool. Data was extracted using a pre-piloted structured data extraction form and synthesized narratively. Reporting was based on PRISMA guideline. Result: A total of 12,644 records were identified. Of these, 21 guidelines were included in this review. Three of the included guidelines were related to coexisting disorders, 11 related to SMI, and 7 guidelines were related to SUD. Seven (out of 18) single disorder guidelines did not adequately recommend the importance of diagnosis or treatment of concurrent disorders despite their high co-prevalence. The majority of the guidelines ( n = 15) lacked recommendations for medicines optimisation in accordance with concurrent disorders (SMI or SUD) such as in the context of drug interactions. Social cause and consequence of dual diagnosis such as homelessness and safeguarding and associated referral pathways were sparsely mentioned. Conclusion: Despite very high co-prevalence, clinical guidelines for SUD or SMI tend to have limited considerations for coexisting disorders in diagnosis, treatment and management. There is a need to improve the scope, quality and inclusivity of guidelines to offer person-centred and integrated care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852 · cited 10×
“CANMAT and ISBD 2018 [57] Yes No No No No No No No”
BackgroundMethodInfluentialAGREE II: advancing guideline development, reporting, and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Preventive Medicine · doi:10.1016/j.ypmed.2010.08.005 · Cited by 758
Integrated treatment of substance use and psychiatric disorders
Kelly, T. M., & Daley, D. C. (2013) · Social Work in Public Health · doi:10.1080/19371918.2013.774673 · Cited by 378
Reus, V. I., Fochtmann, L. J., Bukstein, O., Eyler, A. E., Hilty, D. M., Horvitz-Lennon, M., Mahoney, J., Pasic, J., Weaver, M., Wills, C. D., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.1750101 · Cited by 372
Padgett, D. K., Stanhope, V., Henwood, B. F., & Stefancic, A. (2011) · Community Mental Health Journal · doi:10.1007/s10597-009-9283-7 · Cited by 335
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
McGovern, M. P., Lambert-Harris, C., Gotham, H. J., Claus, R. E., & Xie, H. (2014) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-012-0449-1 · Cited by 126
Treatment of Dual Diagnosis Disorders
Murthy, P., & Chand, P. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328351a3e0 · Cited by 115
Theis (2016) · doi:10.1016/j.cnur.2016.01.007 · Cited by 24
Research works printed but not linked: 49
- Carrà G, Bartoli F, Brambilla G, Crocamo C, Clerici M. Comorbid addiction and major mental illness in Europe: a narrative review. Subst Abus. 2015;36(1):75–81. https://doi.org/10.1080/08897077.2014.960551. · DOI
- Fantuzzi C, Mezzina R. Dual diagnosis: a systematic review of the organization of community health services. Int J Soc Psychiatry. 2020;66(3):300–10. https://doi.org/10.1177/0020764019899975. · DOI · Paper page
- McCreadie RG. Use of drugs, alcohol and tobacco by people with schizophrenia: case–control study. Br J Psychiatry. 2002;181(4):321–5. https://doi.org/10.1192/bjp.181.4.321. · DOI · Paper page
- Temmingh HS, Williams T, Siegfried N, Stein DJ. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. Cochrane Database Syst Rev. 2018;1. · DOI
- Elliott I. Poverty and mental health: a review to inform the Joseph Rowntree Foundation’s Anti-Poverty Strategy. Available from: http://www.patient.co.uk/doctor/Poverty-and-Mental-Health.htm. Accessed 07 Feb 2021.
- Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry. 2006;189(3):229–34. https://doi.org/10.1192/bjp.bp.105.017236. · DOI · Paper page
- Brunette MF, Mueser KT, Drake RE. A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug Alcohol Rev. 2004;23(4):471–81. https://doi.org/10.1080/09595230412331324590. · DOI · Paper page
- Lambert-Harris C, Saunders EC, McGovern MP, Xie H. Organizational capacity to address co-occurring substance use and psychiatric disorders: assessing variation by level of care. J Addict Med. 2013;7(1):25–32. https://doi.org/10.1097/ADM.0b013e318276e7a4. · DOI
- Hjorthøj C, Østergaard MLD, Benros ME, Toftdahl NG, Erlangsen A, Andersen JT, et al. Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. Lancet Psychiatry. 2015;2(9):801–8. https://doi.org/10.1016/S2215-0366(15)00207-2. · DOI · Paper page
- Lynskey MT, Kimber J, Strang J. Drug-related mortality in psychiatric patients. Lancet Psychiatry. 2015;2(9):767–9. https://doi.org/10.1016/S2215-0366(15)00372-7. · DOI
- Fridell M, Bäckström M, Hesse M, Krantz P, Perrin S, Nyhlén A. Prediction of psychiatric comorbidity on premature death in a cohort of patients with substance use disorders: a 42-year follow-up. BMC Psychiatry. 2019;19(1):150. https://doi.org/10.1186/s12888-019-2098-3. · DOI
- Fekadu W, Mihiretu A, Craig TKJ, Fekadu A. Multidimensional impact of severe mental illness on family members: systematic review. BMJ Open. 2019;9(12). · DOI · Paper page
- Lukasiewicz M, Blecha L, Falissard B, Neveu X, Benyamina A, Reynaud M, et al. Dual diagnosis: prevalence, risk factors, and relationship with suicide risk in a nationwide sample of French prisoners. Alcohol Clin Exp Res. 2009;33(1):160–8. https://doi.org/10.1111/j.1530-0277.2008.00819.x. · DOI
- Polcin DL. Co-occurring substance abuse and mental health problems among homeless persons: suggestions for research and practice. J Soc Distress Homeless. 2016;25(1):1–10. https://doi.org/10.1179/1573658X15Y.0000000004. · DOI
- Schütz C, Choi F, Jae Song M, Wesarg C, Li K, Krausz M. Living with dual diagnosis and homelessness: marginalized within a marginalized group. J Dual Diagn. 2019;15(2):88–94. https://doi.org/10.1080/15504263.2019.1579948. · DOI
- Buckley PF. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. J Clin Psychiatry. 2006;67:5. · DOI · Paper page
- McLeod KE, Butler A, Young JT, Southalan L, Borschmann R, Sturup-Toft S, et al. Global prison health care governance and health equity: a critical lack of evidence. Am J Public Health. 2020;110(3):303–8. https://doi.org/10.2105/AJPH.2019.305465. · DOI
- Gunner E, Chandan SK, Yahyouche A, Paudyal V, Marwick S, Saunders K, et al. Provision and accessibility of primary healthcare services for people who are homeless: a qualitative study of patient perspectives in the UK. Br J Gen Pract. 2019;69(685):E526–36. https://doi.org/10.3399/bjgp19X704633. · DOI
- Paudyal V, Maclure K, Forbes-McKay K, McKenzie M, McLeod J, Smith ASD. If I die, I die, I don’t care about my health’: perspectives on self-care of people experiencing homelessness. Health Soc Care Community. 2020;28(1):160–72. https://doi.org/10.1111/hsc.12850. · DOI
- Paudyal V, MacLure K, Buchanan C, Wilson L, Macleod J, Stewart D. ‘When you are homeless, you are not thinking about your medication, but your food, shelter or heat for the night’: behavioural determinants of homeless patients’ adherence to prescribed medicines. Public Health. 2017;148:1–8. https://doi.org/10.1016/j.puhe.2017.03.002. · DOI
- Pinderup P. Challenges in working with patients with dual diagnosis. Adv Dual Diagn. 2018;11(2):60–75. https://doi.org/10.1108/ADD-11-2017-0021. · DOI
- Sorsa M, Greacen T, Lehto J, Åstedt-Kurki P. A qualitative study of barriers to care for people with co-occurring disorders. Arch Psychiatr Nurs. 2017;31(4):399–406. https://doi.org/10.1016/j.apnu.2017.04.013. · DOI
- Ducharme LJ, Knudsen HK, Roman PM. Availability of integrated care for co-occurring substance abuse and psychiatric conditions. Community Ment Health J. 2006;42(4):363–75. https://doi.org/10.1007/s10597-005-9030-7. · DOI
- Stewart SH, Conrod PJVO-19. State-of-the-art in cognitive-behavioral interventions for substance use disorders: introduction to the special issue. J Cogn Psychother. 2005;19(3):195.
- Perron BE, Bunger A, Bender K, Vaughn MG, Howard MO. Treatment guidelines for substance use disorders and serious mental illnesses: do they address co-occurring disorders? Subst Use Misuse. 2010;45(7–8):1262–78. https://doi.org/10.3109/10826080903442836. · DOI
- Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed1000097. · doi:10.1371/journal.pmed1000097
- Mclellan AT. Substance misuse and substance use disorders: why do they matter in healthcare? Trans Am Clin Climatol Assoc. 2017;128:112.
- Brouwers MC, Kerkvliet K, Spithoff K, Consortium ANS. The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines. BMG. 2016;352:i1152.
- National Institute for Health and Care Excellence (NICE). Psychosis with coexisting substance misuse: assessment and management in adults and young people. Available from: https://www.ncbi.nlm.nih.gov/books/NBK109783/pdf/Bookshelf_NBK109783.pdf. Accessed 07 Feb 2021.
- Soyka M, Kranzler HR, Hesselbrock V, Kasper S, Mutschler J, Möller HJ. Guidelines for biological treatment of substance use and related disorders, part 1: alcoholism, first revision. World J Biol Psychiatry. 2017;18(2):86–119. https://doi.org/10.1080/15622975.2016.1246752. · DOI · Paper page
- Preuss UW, Gouzoulis-Mayfrank E, Havemann-Reinecke U, Schäfer I, Beutel M, Hoch E, et al. Psychiatric comorbidity in alcohol use disorders: results from the German S3 guidelines. Eur Arch Psychiatry Clin Neurosci. 2018;268(3):219–29. https://doi.org/10.1007/s00406-017-0801-2. Accessed 07 Feb 2021. · DOI
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 3: update 2015 management of special circumstances: depression, Suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16(3):142–70. https://doi.org/10.3109/15622975.2015.1009163. · DOI · Paper page
- Castle DJ, Galletly CA, Dark F, Humberstone V, Morgan VA, Killackey E, et al. The 2016 royal australian and New Zealand college of psychiatrists guidelines for the management of schizophrenia and related disorders. Med J Aust. 2017;206(11):501–5. https://doi.org/10.5694/mja16.01159. · DOI
- Barnes TRE, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3–78. https://doi.org/10.1177/0269881119889296. · DOI · Paper page
- Mok YM, Chan HN, Chee KS, Chua T-E, Lim BL, Marziyana AR, et al. MOH clinical practice guidelines: bipolar disorder. Ministry of Health. Available from: https://pubmed.ncbi.nlm.nih.gov/22159936/. Accessed 07 Feb 2021.
- Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes TRH, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495–553. https://doi.org/10.1177/0269881116636545. · DOI · Paper page
- Keating D, McWilliams S, Schneider I, Hynes C, Cousins G, Strawbridge J, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7(1):e013881. https://doi.org/10.1136/bmjopen-2016-013881. · DOI · Paper page
- Johnston A, Hsieh S-C, Carrier M, Kelly SE, Bai Z, Skidmore B, et al. A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: implications for research and policy decision-making. PLoS One. 2018;13(11):e0207410. https://doi.org/10.1371/journal.pone.0207410. · DOI
- Zhang P, Lu Q, Li H, Wang W, Li G, Si L, et al. The quality of guidelines for diabetic foot ulcers: a critical appraisal using the AGREE II instrument. PLoS One. 2019;14(9):e0217555. https://doi.org/10.1371/journal.pone.0217555. · DOI
- Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract. 2005;11(5):315–39. https://doi.org/10.1097/00131746-200509000-00005. · DOI · Paper page
- Morrens M, Dewilde B, Sabbe B, Dom G, De Cuyper R, Moggi F. Treatment outcomes of an integrated residential programme for patients with schizophrenia and substance use disorder. Eur Addict Res. 2011;17(3):154–63. https://doi.org/10.1159/000324480. · DOI · Paper page
- Bowen M, Marshall T, Yahyouche A, Paudyal V, Marwick S, Saunders K, et al. Multimorbidity and emergency department visits by a homeless population: a database study in specialist general practice. Br J Gen Pract. 2019;69(685):E515–25. https://doi.org/10.3399/bjgp19X704609. · DOI
- Moxley VBA, Hoj TH, Novilla MLB. Predicting homelessness among individuals diagnosed with substance use disorders using local treatment records. Addict Behav. 2020;102:106160. https://doi.org/10.1016/j.addbeh.2019.106160. · DOI
- Field G. Continuity of offender treatment for substance use disorders from institution to community: treatment improvement protocol (TIP) series 30. Washington, DC: Department of Health and Human Services; 1998.
- Paudyal V, Gibson Smith K, MacLure K, Forbes-McKay K, Radley A, Stewart D. Perceived roles and barriers in caring for the people who are homeless: a survey of UK community pharmacists. Int J Clin Pharm. 2019;41(1):215–27. https://doi.org/10.1007/s11096-019-00789-4. · DOI
- Jagpal P, Saunders K, Plahe G, Russell S, Barnes N, Lowrie R, et al. Research priorities in healthcare of persons experiencing homelessness: outcomes of a national multi-disciplinary stakeholder discussion in the United Kingdom. Int J Equity Health. 2020;19(1):1–7 https://doi.org/10.1186/s12939-020-01206-3. · DOI
- Jagpal P, Barnes N, Lowrie R, Banerjee A, Paudyal V. Clinical pharmacy intervention for persons experiencing homelessness: evaluation of patient perspectives in service design and development. Pharmacy. 2019;7(4):153. https://doi.org/10.3390/pharmacy7040153. · DOI
- Alenezi A, Yahyouche A, Paudyal V. Interventions to optimize prescribed medicines and reduce their misuse in chronic non-malignant pain: a systematic review. Eur J Clin Pharmacol. 2021;77(4):467–90. · DOI
- Ali RA, Jalal Z, Paudyal V. Barriers to monitoring and management of cardiovascular and metabolic health of patients prescribed antipsychotic drugs: a systematic review. BMC Psychiatry. 2020;20(1) https://doi.org/10.1186/s12888-020-02990-6. · DOI
Cited by
Halladay, J., Horricks, L., Amlung, M., MacKillop, J., Munn, C., Nasir, Z., Woock, R., & Georgiades, K. (2021) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-021-00403-4 · Cited by 8
Halladay, J., Stead, V., McCarron, C., Kennedy, M., King, K., Venantius, M., Carter, A., Syan, S., Matthews, M., Khoshroo, S., et al. (2022) · medRxiv · doi:10.1101/2022.10.21.22281362 · Cited by 5
“9 screening and treatment of both substance use and other mental health disorders (34) and CBT is”
BackgroundBratt, S. (2025) · Discover Public Health · doi:10.1186/s12982-025-00743-y · Cited by 2
Metadata
- Authors
- Alsuhaibani, R., Smith, D. C., Lowrie, R., Aljhani, S., & Paudyal, V.
- Venue
- BMC Psychiatry
- Published
- 2021-04-23
- Volume
- 21
- Issue
- 1
- Pages
- 209-209
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W3155073635
- Cited by
- 97
- References
- 10
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review. https://app.cochat.ai/papers/10.1186/s12888-021-03188-0
- The paper
- Alsuhaibani, R., Smith, D. C., Lowrie, R., Aljhani, S., & Paudyal, V. (2021). Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review. BMC Psychiatry. https://doi.org/10.1186/s12888-021-03188-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.